Congress Returns to Washington for “Lame Duck” Session and to Complete Work for 2024 Following the November elections, Congress will return to Washington, D.C., to complete work on federal funding and a package of several pieces of health legislation including many priorities of the Endocrine Society. Federal funding for the government expires December 20, 2024,...
Webinar Will Examine Concerns Around Compounding Anti-Obesity Medications
Endocrine Society to host virtual Science Writers Conference Nov. 14 Surging demand for a new generation of highly effective anti-obesity medications is creating interest in compounded versions of these medications. Endocrine Society experts will discuss the importance of prescribing FDA-approved medications to treat obesity during the Society’s Virtual Science Writers Conference on November 14. What:...
On the heels of receiving nearly $10 million from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Rohit N. Kulkarni, MD, PhD, discusses how his team will use this grant to pursue new approaches to studying type 2 diabetes and obesity by exploring gene expression and regulatory activity in multiple metabolic cells. ...
Innovations on the forefront of glucose monitoring and insulin delivery are revolutionizing the state of diabetes care. Staying abreast of the latest advancements in diabetes technology is critical for improving patient care. The field of diabetes management continues to rapidly evolve with products designed to optimize glucose monitoring, insulin delivery, and patient convenience. Next-generation continuous...
Talking Obesity with Daniel J. Drucker, Co-Inventor of Ozempic
Daniel Drucker, MD, recent winner of our Lifetime Achievement Laureate Award, the top honors in the field, shares his story as one of the pioneers in advancing next-generation anti-obesity medications such as Ozempic in a new video series on obesity care. Drucker, who is a senior investigator at the Lunenfeld-Tanenbaum Research Institute, Sinai Health, and a...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * First Successful Clinical Trial with Anti-CD40L Antibody is Completed On October 29, a potentially major advancement for type 1 diabetes treatment was announced by the University of Miami Diabetes Research Institute (UM-DRI), in collaboration with the University of Chicago, regarding the...
SIG Webinar Attendees Learn About Various Scientific Pathways
A Town Hall sponsored by the Endocrine Society’s Early-Career Special Interest Group (SIG) provided attendees with insight into the professional journeys of a basic scientist, a translational scientist, and a physician-scientist. The Early-Career Special Interest Group (SIG) Webinar “Insider Insights in the Scientist Pathway” welcomed three highly accomplished professors last week, who each shared valuable...
Endocrine Society Members Elected to the National Academy of Medicine
Endocrine Society members David J. Mangelsdorf, PhD; Erica Elizabeth Marsh, MD, MSCI; and Margaret M. McCarthy, PhD have been elected to the National Academy of Medicine (NAM). David J. Mangelsdorf, PhD, is professor and chair, department of pharmacology, and investigator, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas. He was noted for...
